http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#Head
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#assertion
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#provenance
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#pubinfo
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#assertion
http://purl.obolibrary.org/obo/DOID_9408
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9408
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00009
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
http://www.w3.org/2000/01/rdf-schema#label
activase is a tissue plasminogen activator tpa indicated for the treatment of acute ischemic stroke ais 1 1 acute myocardial infarction ami to reduce mortality and incidence of heart failure 1 2 limitation of use in ami 1 2 acute massive pulmonary embolism pe for lysis 1 3 activase is indicated for the treatment of acute ischemic stroke exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment see contraindications 4 1 activase is indicated for use in acute myocardial infarction ami for the reduction of mortality and reduction of the incidence of heart failure limitation of use activase is indicated for the lysis of acute massive pulmonary embolism defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments acute pulmonary emboli accompanied by unstable hemodynamics e g failure to maintain blood pressure without supportive measures
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00009
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#provenance
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#pubinfo
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig
http://purl.org/nanopub/x/hasSignature
GGqC+dUkQJsevZ3+T+JhWKjrtiuZIL6hh7wB/cxWj1dnFa01sWa3muqHyDB6IasMu5zjmUuE1FWL5vTFT6p5agmqiikOFi2Ip5qReoJ8YlsglwntIqw3lgahzhOG88VIdmQtUlFo2D0Xfdlhx8E9EsNX0Ix77/f2l3Qrxj7xMWo=
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://purl.org/dc/terms/created
2021-06-12T12:20:18.779+02:00
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs